SARS-CoV-2: Targeted managements and vaccine development.
SARS-CoV-2: Targeted managements and vaccine development.
复制标题
DOI：
10.1016/j.cytogfr.2020.11.001
复制
发表时间：
2021-04
影响因子：
13
通讯作者：
Taurin S
中科院分区：
文献类型：
--
作者：
Bakhiet M;Taurin S
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染导致不同的结果。在65岁以上的男性和有潜在健康状况的人中，症状似乎更严重;全球约有五分之一的人可能面临风险。该病毒的序列在第一例病例报告后几天迅速建立，并确定了一种来自冠状病毒科的RNA病毒，与中国蝙蝠中发现的β冠状病毒密切相关。SARS-CoV-2是已知感染人类的第七种冠状病毒，与严重急性呼吸综合征（SARS）和中东呼吸综合征（MERS）一起，是唯一导致严重疾病的冠状病毒。从这两次爆发中吸取的教训指导了关键治疗靶点的鉴定，例如通过多种类型真核细胞表面上表达的血管紧张素转换酶2（ACE 2）受体促进病毒进入细胞的刺突病毒蛋白。虽然目前正在评估几种治疗药物，但似乎没有一种药物能提供明确的治愈途径。此外，在创纪录的时间内开发了各种类型的疫苗，以解决有效预防SARS-CoV-2的紧迫性。目前，有58种疫苗在临床试验中进行评估，其中11种处于III期，其中3种报告的有效性超过90%。到目前为止，临床试验的结果表明，在几个月内可以获得多种有效的疫苗。
Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) results in diverse outcomes. The symptoms appear to be more severe in males older than 65 and people with underlying health conditions; approximately one in five individuals could be at risk worldwide. The virus’s sequence was rapidly established days after the first cases were reported and identified an RNA virus from the Coronaviridae family closely related to a Betacoronavirus virus found in bats in China. SARS-CoV-2 is the seventh coronavirus known to infect humans, and with the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), the only ones to cause severe diseases. Lessons from these two previous outbreaks guided the identification of critical therapeutic targets such as the spike viral proteins promoting the virus’s cellular entry through the angiotensin-converting enzyme 2 (ACE2) receptor expressed on the surface of multiple types of eukaryotic cells. Although several therapeutic agents are currently evaluated, none seems to provide a clear path for a cure. Also, various types of vaccines are developed in record time to address the urgency of efficient SARS-CoV-2 prevention. Currently, 58 vaccines are evaluated in clinical trials, including 11 in phase III, and 3 of them reported efficacy above 90 %. The results so far from the clinical trials suggest the availability of multiple effective vaccines within months.
DOI：
10.1056/nejmoa2028436
发表时间：
2020-12-17
期刊：
The New England journal of medicine
影响因子：
--
作者：
Anderson EJ;Rouphael NG;Widge AT;Jackson LA;Roberts PC;Makhene M;Chappell JD;Denison MR;Stevens LJ;Pruijssers AJ;McDermott AB;Flach B;Lin BC;Doria-Rose NA;O'Dell S;Schmidt SD;Corbett KS;Swanson PA 2nd;Padilla M;Neuzil KM;Bennett H;Leav B;Makowski M;Albert J;Cross K;Edara VV;Floyd K;Suthar MS;Martinez DR;Baric R;Buchanan W;Luke CJ;Phadke VK;Rostad CA;Ledgerwood JE;Graham BS;Beigel JH;mRNA-1273 Study Group
通讯作者：
mRNA-1273 Study Group